OTLK
NASDAQ HealthcareOutlook Therapeutics, Inc. - Common Stock
Biotechnology
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
๐ Market Data
| Price | $0.67 |
|---|---|
| Volume | 79,863,722 |
| Market Cap | 125.70M |
| Beta | 0.800 |
| RSI (14-Day) | 39.4 |
| 200-Day MA | $0.91 |
| 50-Day MA | $1.28 |
| 52-Week High | $3.39 |
| 52-Week Low | $0.16 |
| Forward P/E | -4.20 |
| Price / Book | -1.13 |
๐ฏ Investment Strategy Scores
OTLK scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (94/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find OTLK in your text
Paste any article, transcript, or post โ the tool will extract OTLK and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.